RecruitingPHASE1, PHASE2NCT04657068
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Studying Acinar cell carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Artios Pharma Ltd
- Principal Investigator
- Melissa Johnson, MDTennessee Oncology
- Intervention
- ART0380(drug)
- Enrollment
- 442 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Mayo Clinic (Arizona), Scottsdale, Arizona, United States
- University of Arkansas - Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Sansum Clinic, Santa Barbara, California, United States
- Providence Medical Foundation, Santa Rosa, California, United States
- Rocky Mountain Cancer Center, Denver, Colorado, United States
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
- Florida Cancer Specialists, Fort Myers, Florida, United States
- Mayo Clinic (Florida), Jacksonville, Florida, United States
- Cancer Specialists of North Florida, Jacksonville, Florida, United States
- Florida Cancer Specialists, Orlando, Florida, United States
- Florida Cancer Specialists, Sarasota, Florida, United States
- Florida Cancer Specialists, West Palm Beach, Florida, United States
- Hope and Healing Cancer Services, Hinsdale, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04657068 on ClinicalTrials.govOther trials for Acinar cell carcinoma of pancreas
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic CancerAlliance for Clinical Trials in Oncology
- RECRUITINGPHASE2NCT04858334APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT04150042SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem CellsGeneral Oncology, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT02834013Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)
- RECRUITINGNANCT02757859High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by SurgerySidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- ACTIVE NOT RECRUITINGPHASE1NCT00669734Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By SurgeryNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE1NCT00878163GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by SurgeryNational Cancer Institute (NCI)